Skip to main content

Table 2 Anti-HCV Treatment characteristics of patients according to treatment arm

From: The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals

  HIV-negative   HIV-positive  
   No HAART NRTI-containing NRTI-free
  Arm A Arm B Arm C1 Arm C2
  n = 50 n = 49 n = 49 n = 20
Weight adapted RBV * (GT1/4 infections only) 96 81 77 82
Treatment duration 48 weeks
(GT 2/3 infections only) *
0 35 35 67
Enrollment period */**     
    2002 - 2004 100 80 55 30
    2005 - 2007 - 20 43 70
  1. * Statistically significant difference comparing arm A with arms B and C (HIV-positive vs. HIV-negative)
  2. ** Statistically significant difference comparing arm B versus C1 versus C2
  3. Data shown as percent of patients
  4. NRTI nucleos(t)ide reverse transcriptase inhibitor, GT HCV genotype, RBV ribavirin